Leveraging Our Biostatistics Services for Successful Medical Device Validation and Clinical Trials
Medical device studies involve smaller target populations, evolving device iterations, surgical learning curves, and complex endpoints like time-to-device failure or diagnostic accuracy. Meeting FDA (510(k), De Novo, PMA) or EU MDR requirements demands statistical planning that accounts for these specific variables.
Anatomise Biostats provides specialised biostatistics support to medical device start-ups and SMEs. We integrate statistical precision into your clinical validation process—from early feasibility studies (EFS) to pivotal clinical trials and post-market clinical follow-up (PMCF)—so that your data withstands regulatory scrutiny.
Schedule a Discovery Call
The Role of Biostatistics in Device Development
Precise study design and accurate sample size calculations prevent costly delays caused by protocol amendments or underpowered results. Efficient designs reduce unnecessary patient enrolment, shortening the timeline to market.
Properly analysed data provides an objective view of the device’s performance. It identifies potential safety signals, mechanical flaws, or suboptimal performance in specific patient subgroups early in the development cycle, preventing costly post-market failures.
A clinical trial designed and analysed by an independent biostatistics team produces data that regulators and investors trust. Clear, statistically sound evidence is frequently the limiting factor in securing Series B/C funding or achieving device approval.
Clinical Study Design for Medical Devices
A statistically sound design is required to isolate the true effect of the device from confounding variables, such as operator experience or patient heterogeneity. We collaborate with your team to develop study protocols aligned with ISO 14155 and ICH E9(R1) guidelines. This includes:
Defining primary and secondary endpoints that reflect clinically meaningful outcomes, while specifying estimands that account for intercurrent events (e.g., device revisions, protocol deviations, or concomitant medication changes).
Designing appropriate controls, including historical controls, literature-based performance goals, or sham controls, which are frequently required for device studies.
For surgical devices and novel technologies, we implement statistical models (e.g., cumulative sum (CUSUM) analysis) to evaluate and adjust for the operator learning curve, so clinical trial results reflect the device’s true efficacy rather than early user inexperience.
Implementing adaptive study designs or Bayesian approaches (often favoured by the FDA for devices) to allow for mid-study modifications based on accumulating data without compromising study integrity or inflating Type I error.
Sample Size Determination
Underpowered studies risk failing to demonstrate device effectiveness, while overpowered studies waste resources and expose unnecessary patients to risk. We calculate sample sizes based on your device’s anticipated effect size, variance estimates, and expected attrition rates.
For complex adaptive designs or novel endpoints where standard formulae do not apply, we use Monte Carlo simulations to model multiple scenarios and determine the precise sample size needed to achieve adequate statistical power.
When testing multiple endpoints or conducting subgroup analyses, we apply hierarchical testing and gatekeeping strategies to control the family-wise error rate (FWER) and satisfy regulatory requirements.
Statistical Methods and Analytics
We apply statistical techniques specifically suited to the mechanics and data structures of medical devices:
Used heavily for implantable devices. We use Kaplan-Meier estimation for time-to-event curves (e.g., time to target lesion failure) and Cox proportional hazards models to adjust for patient covariates. For devices where patient death precludes the observation of device failure, we employ competing risks regression (Fine-Gray subdistribution hazard models).
Necessary when data has a hierarchical structure—such as multiple measurements per patient or patients treated by multiple surgeons across different sites. These models isolate the device’s effect from random effects like surgeon skill or site-specific patient volumes.
Frequently used for 510(k) submissions to prove a new device is as safe and effective as a legally marketed predicate. We calculate non-inferiority margins based on historical data (preserving a fraction of the effect) and apply appropriate one-sided tests.
For IVDs and diagnostic devices, we calculate sensitivity, specificity, PPV, and NPV. For continuous data agreement, we utilise Passing-Bablok regression (which handles measurement error in both the test and reference method) and Bland-Altman plots, alongside Intraclass Correlation Coefficients (ICC) for inter-rater reliability.
For rare disease indications or paediatric devices, we utilise Bayesian hierarchical models to “borrow strength” from historical control data, applying discounting functions to prevent borrowed data from overly influencing the study outcomes.
Handling Missing Data and Sensitivity Analyses
Missing data is inevitable in long-term device studies due to patient dropouts or lost-to-follow-up.
Rather than relying on flawed complete-case analysis, we use Multiple Imputation by Chained Equations (MICE) or Mixed Models for Repeated Measures (MMRM) to handle missing data points without biasing the results.
Regulatory bodies increasingly require tipping point analyses to determine the exact threshold at which missing data would overturn the study’s conclusion, proving the robustness of the primary findings.
Data Quality and Independent Integrity
Regulatory bodies require clear separation between the study sponsor and the independent analysts to prevent confirmation bias. As an independent CRO, we take over data-related tasks from database build to database lock.
We structure data collection and analysis using CDASH and SDTM standards, which are increasingly expected by the FDA and required for certain submissions.
We implement strict data management plans adhering to ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate, and Complete) principles, running automated edit checks to identify data anomalies and protocol deviations before database lock.
Regulatory Compliance and Submissions
Generating a statistical report that satisfies FDA, MHRA, or EU MDR reviewers requires specific formatting and justification.
We draft detailed SAPs that lock the analysis methodology before unblinding the data, maintaining regulatory compliance.
We prepare the statistical sections for your Clinical Evaluation Report (CER) for EU MDR or IDE (Investigational Device Exemption) application for the FDA.
We provide direct statistical support during FDA Pre-Submission (Pre-Sub) meetings or Notified Body reviews. We justify the chosen methodologies, defend non-inferiority margins, and address statistical queries from reviewers directly.